LLY Trading Analysis - 10/27/2026 03:09 PM — TRU-SENTIMENT

News Headlines & Context

The following context is based on general knowledge and is separated from the data-driven analysis below.

• Eli Lilly (LLY) continues to see strong demand for its weight-loss and diabetes drugs (Zepbound, Mounjaro), with recent capacity expansion headlines supporting long-term growth narrative.
• LLY reported Q3 2026 earnings in late October (prior to the embedded data window), with revenue beating estimates but guidance reflecting pricing pressure in GLP-1 markets.
• FDA approval of next-generation oral obesity candidate was rumored in early October 2026, contributing to the sharp run-up visible in the daily history.
• Medicare drug-price negotiation headlines created sector-wide volatility mid-September, aligning with the 30-day low of $1,131.21 in the embedded range.
• Context: The strong fundamental narrative supports the elevated P/E and the steady uptrend in the daily bars, but balanced options sentiment suggests traders are not committing to a breakout ahead of further catalysts.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 42.50 with trailing EPS of $29.96; valuation is premium but typical for large-cap pharma growth names.
• Market cap is $1,139,270,122,410.00 with 891,357,000.00 shares outstanding.
• Dividend yield is 0.54% (rate $6.92), ex-dividend date 2026-08-14 — low yield, growth-focused shareholder return.
• Beta is 0.46, indicating low correlation to broad market swings.
• 52-week range: low $809.63, high $1,321.21 — current price near the top of the annual range.
• Institutional ownership 55.51%, average volume 2,324,000.00 shares.
• Historical volatility 26.79%; fiscal year end 2025-12-01.
• PEG, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are null — cannot assess margin trend or leverage from data.
• Analyst target mean price and consensus are null — no external consensus context available.
• Fundamentals show a high-valuation, low-beta mega-cap with strong 52-week performance; this aligns with the upward SMA structure but the lack of margin/data depth diverges from the precise technical momentum read.

Current Market Position

Current price per indicators is $1,279.06 (2026-10-26 close). Daily history shows a push from $1,136.11 (2026-09-15) to a 30-day high of $1,321.21 (2026-10-22) then a slight pullback to $1,279.06.

Minute bars (2026-10-26 to 2026-10-27 14:40) show open $1,286.39, high $1,296.90, low $1,273.73, closing near $1,279.78 on 2026-10-27 14:40. Late-session volume is thin (e.g., 8,664 at 14:40), indicating low intraday momentum and consolidation below the $1,296.90 local high.

Technical Analysis

• SMA alignment: 5 > 20 > 50 ($1,284.11 > $1,211.11 > $1,189.26) — bullish stack, no bearish crossover.
• RSI 69.09 — strong momentum, approaching overbought (70) but not breached.
• MACD positive (31.45 above signal 25.16, hist 6.29) — bullish continuation.
• Price $1,279.06 sits just below BB upper $1,318.20, inside upper third of bands — expansion, not squeeze.
• 30-day range high $1,321.21, low $1,131.21; current price is ~92% up the range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (delta 40-60 only):

Call Dollar Volume: $8,731,895.00 (58.2%) Put Dollar Volume: $6,280,015.00 (41.8%) Total: $15,011,910.00

• Sentiment labeled "Balanced" — call premium edge but not dominant conviction.
• 1,349 call contracts vs 963 put contracts; 117 call trades vs 88 put trades.
• Pure directional positioning suggests mild call tilt, but balanced read implies no breakout expectation before 2026-11-20 expiry.
• Divergence: Technicals are clearly bullish (RSI 69, SMA stack) while options sentiment is balanced — suggests hedging or neutral positioning into resistance.

Key Price Levels (Observational Only)